• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    KBRA Assigns Preliminary Ratings to VRTX 2025-HQ

    8/1/25 1:14:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRTX alert in real time by email

    KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 billion fixed rate, interest-only first lien mortgage loan. The fixed-rate loan has a five-year term and requires monthly interest-only payments based on an assumed interest rate of 6.25%. The loan is secured by the borrower's fee simple interest in Vertex HQ , two 15-story, Class-A, LEED Gold office tower containing 1.1 million sf. The building is located in the Seaport neighborhood of downtown Boston. The buildings were developed in 2013 as a built-to-suit corporate headquarters for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). KBRA performed a credit estimate on Vertex, and the results of the analysis indicated that Vertex has credit characteristics consistent with an entity with an investment grade rating. Vertex leases all of the office and lab space at the property and represents 96.8% of base rent. The tenant recently renewed its lease through 2044, or approximately 14 years beyond the loan term.

    KBRA's analysis of the transaction included a detailed evaluation of the property's cash flows using our North American CMBS Property Evaluation Methodology and the application of our North American CMBS Single Borrower & Large Loan Rating Methodology. In addition, KBRA also relied on its Global Structured Finance Counterparty Methodology for assessing counterparty risk in this transaction, and its ESG Global Rating Methodology, to the extent deemed applicable.

    The results of our analysis yielded a KBRA net cash flow (KNCF) for the subject of approximately $87.6 million, which is 4.7% below the issuer's NCF, and a KBRA value of $1.06 billion, which is 34.7% below the appraiser's value. The resulting in-trust KBRA Loan to Value (KLTV) is 94.2%. In our analysis of the transaction, we also reviewed and considered third party engineering, environmental, and appraisal reports, the results of our site inspection of the property, and legal documentation review.

    To access ratings and relevant documents, click here.

    Click here to view the report.

    Methodologies

    • CMBS: North American CMBS Property Evaluation Methodology
    • CMBS: North American CMBS Single Borrower & Large Loan Rating Methodology
    • Structured Finance: Global Structured Finance Counterparty Methodology
    • ESG Global Rating Methodology

    Disclosures

    Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above.

    A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here.

    Information on the meaning of each rating category can be located here.

    Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com.

    About KBRA

    Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S.

    Doc ID: 1010618

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250801658787/en/

    Analytical Contacts

    Kevin Gibson, Associate Director (Lead Analyst)

    +1 646-731-1202

    [email protected]

    Patrick McQuinn, Senior Director

    +1 646-731-2445

    [email protected]

    Nitin Bhasin, Senior Managing Director, Global Head of CMBS (Rating Committee Chair)

    +1 646-731-2334

    [email protected]

    Business Development Contact

    Andrew Foster, Senior Director

    +1 646-731-1470

    [email protected]

    Get the next $VRTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRTX

    DatePrice TargetRatingAnalyst
    8/6/2025$460.00Equal Weight → Overweight
    Wells Fargo
    5/7/2025Outperform → Peer Perform
    Wolfe Research
    5/6/2025$503.00Outperform → Market Perform
    Leerink Partners
    4/22/2025$535.00Overweight
    Cantor Fitzgerald
    2/12/2025$408.00 → $424.00Sell → Hold
    Canaccord Genuity
    2/11/2025Sell → Hold
    Canaccord Genuity
    1/30/2025$460.00Overweight → Equal Weight
    Wells Fargo
    12/20/2024$600.00 → $535.00Buy
    H.C. Wainwright
    More analyst ratings

    $VRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vertex Reports Second Quarter 2025 Financial Results

    — Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion — — Continued strong execution of CASGEVY®, ALYFTREK® and JOURNAVX® launches — — Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine in DPN, zimislecel in T1D, povetacicept in IgAN and pMN, and inaxaplin in AMKD — — David Altshuler, M.D., PhD., Chief Scientific Officer (CSO), announces intent to retire August 1, 2026; as part of planned transition, Mark Bunnage, D.Phil., SVP of Global Research, to assume role of CSO effective February 1, 2026 — Vertex Pharmaceuticals Incor

    8/4/25 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

    – Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – – Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-w

    8/4/25 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KBRA Assigns Preliminary Ratings to VRTX 2025-HQ

    KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 billion fixed rate, interest-only first lien mortgage loan. The fixed-rate loan has a five-year term and requires monthly interest-only payments based on an assumed interest rate of 6.25%. The loan is secured by the borrower's fee simple interest in Vertex HQ , two 15-story, Class-A, LEED Gold office tower containing 1.1 million sf. The building is located in the Seaport neighborhood of downtown Boston. The buildings were developed in 2013 as a built-to-suit corporate headquarters for Vertex Pharma

    8/1/25 1:14:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vertex Pharma upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Vertex Pharma from Equal Weight to Overweight and set a new price target of $460.00

    8/6/25 7:57:36 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Pharma downgraded by Wolfe Research

    Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform

    5/7/25 8:37:12 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Pharma downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00

    5/6/25 8:04:29 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Kewalramani Reshma bought $3,895,768 worth of shares (10,000 units at $389.58), increasing direct ownership by 9% to 115,968 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:23:31 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sachs Bruce I bought $1,948,416 worth of shares (5,000 units at $389.68), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:19:03 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRTX
    SEC Filings

    View All

    SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated

    10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

    8/5/25 4:02:33 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

    8/4/25 4:06:07 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    5/21/25 4:58:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

    Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

    8/4/23 4:36:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    4/10/24 12:14:10 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/13/24 5:17:31 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/9/24 6:19:03 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRTX
    Financials

    Live finance-specific insights

    View All

    Vertex Reports Second Quarter 2025 Financial Results

    — Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion — — Continued strong execution of CASGEVY®, ALYFTREK® and JOURNAVX® launches — — Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine in DPN, zimislecel in T1D, povetacicept in IgAN and pMN, and inaxaplin in AMKD — — David Altshuler, M.D., PhD., Chief Scientific Officer (CSO), announces intent to retire August 1, 2026; as part of planned transition, Mark Bunnage, D.Phil., SVP of Global Research, to assume role of CSO effective February 1, 2026 — Vertex Pharmaceuticals Incor

    8/4/25 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex to Announce Second Quarter 2025 Financial Results on August 4th

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived we

    7/8/25 4:00:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Reports First Quarter 2025 Financial Results

    — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

    5/5/25 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Kewalramani Reshma bought $3,895,768 worth of shares (10,000 units at $389.58), increasing direct ownership by 9% to 115,968 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:23:31 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sachs Bruce I bought $1,948,416 worth of shares (5,000 units at $389.68), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:19:03 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Upadhyay Suketu

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    7/17/25 4:09:19 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Vertex Appoints Nancy Thornberry to its Board of Directors

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

    12/5/23 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Appoints Michel Lagarde to its Board of Directors

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of

    10/5/23 8:00:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa

    8/29/23 9:00:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care